| 1 | t 49 089 614 | | | | | | | 5 | 0.21% |
| 2 | officer t 49 089 | | | | | | | 4 | 0.17% |
| 3 | scirhom establishes a worldclass | | | | | | | 3 | 0.13% |
| 4 | development of its first | | | | | | | 3 | 0.13% |
| 5 | at weill cornell medicine | | | | | | | 3 | 0.13% |
| 6 | from the university of | | | | | | | 3 | 0.13% |
| 7 | cmc development of its | | | | | | | 3 | 0.13% |
| 8 | of its first drug | | | | | | | 2 | 0.08% |
| 9 | drug candidate for clinical | | | | | | | 2 | 0.08% |
| 10 | at the hospital for | | | | | | | 2 | 0.08% |
| 11 | in new york city | | | | | | | 2 | 0.08% |
| 12 | surgery in new york | | | | | | | 2 | 0.08% |
| 13 | special surgery in new | | | | | | | 2 | 0.08% |
| 14 | tissue degeneration program at | | | | | | | 2 | 0.08% |
| 15 | files clinical trial application | | | | | | | 2 | 0.08% |
| 16 | hospital for special surgery | | | | | | | 2 | 0.08% |
| 17 | and tissue degeneration program | | | | | | | 2 | 0.08% |
| 18 | arthritis and tissue degeneration | | | | | | | 2 | 0.08% |
| 19 | the arthritis and tissue | | | | | | | 2 | 0.08% |
| 20 | of the arthritis and | | | | | | | 2 | 0.08% |
| 21 | prof dr axel ullrich | | | | | | | 2 | 0.08% |
| 22 | biology at weill cornell | | | | | | | 2 | 0.08% |
| 23 | systems biology at weill | | | | | | | 2 | 0.08% |
| 24 | and systems biology at | | | | | | | 2 | 0.08% |
| 25 | the hospital for special | | | | | | | 2 | 0.08% |
| 26 | gmbh formerly scimab gmbh | | | | | | | 2 | 0.08% |
| 27 | starts cmc development of | | | | | | | 2 | 0.08% |
| 28 | firstinhuman trials of novel | | | | | | | 2 | 0.08% |
| 29 | al j clin invest | | | | | | | 2 | 0.08% |
| 30 | the board of directors | | | | | | | 2 | 0.08% |
| 31 | on the board of | | | | | | | 2 | 0.08% |
| 32 | scirhom files clinical trial | | | | | | | 2 | 0.08% |
| 33 | clinical trial application for | | | | | | | 2 | 0.08% |
| 34 | trial application for firstinhuman | | | | | | | 2 | 0.08% |
| 35 | application for firstinhuman trials | | | | | | | 2 | 0.08% |
| 36 | for firstinhuman trials of | | | | | | | 2 | 0.08% |
| 37 | trials of novel antibody | | | | | | | 2 | 0.08% |
| 38 | scirhom starts cmc development | | | | | | | 2 | 0.08% |
| 39 | of novel antibody against | | | | | | | 2 | 0.08% |
| 40 | novel antibody against autoimmune | | | | | | | 2 | 0.08% |